Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro

Anti-Cancer Drugs

Volumn 15, Issue 1, 2004, Pages 55-61

  Chen, Danqing ^a   Hackl, Wolfgang ^b   Ortmann, Olaf ^a   Treeck, Oliver ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Pharmacia Oncology GmbH Germany   (Germany)

Author keywords

Aromatase; Cell growth; Exemestane; Paclitaxel; Tumor cell line

Indexed keywords

ANDROSTENEDIONE; AROMATASE; ESTROGEN RECEPTOR; EXEMESTANE; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER CELL; CELL COUNT; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENDOMETRIUM CARCINOMA; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 4344614174     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200401000-00009     Document Type: Article

References (22)

1. Brodie A. Aromatase, its inhibitors and their use in breast cancer treatment. Pharmacol Ther 1993; 60:501-515.
2. Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 2001; 142:4589-4594.
3. Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausa! women with metastatic breast cancer. J Clin Oncol 1999; 17:3418-3425.
4. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clin Breast Cancer 2000; 1(suppl 1):15-18.
5. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4:2089-2093.
6. Lonning PE. Pharmacology of new aromatase inhibitors. Breast 1996; 5:206-208.
7. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999; 10:377-384.
8. Lonning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18:2234-2244.
9. Schmitt E, Stopper H. Estrogenic activity of naturally occurring anthocyanidins. Nutr Cancer 2001; 41:145-149.
10. Hochner-Celnikier D, Greenfield C, Finci-Yeheskel Z, Milwidisky A, Gutman A, Goldman-Wohl D, et al. Tamoxifen exerts oestrogen-agonistic etfects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression in endometrial adenocarcinoma cells. Mol Hum Reprod 1997; 3:1019-1027.
11. Brandenberger AM, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNA in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines, down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab. 1998; 83:1025-1028.
12. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 1985; 37:1103-11.
13. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18:1399-1411.
14. Paridaens R, Thomas J, Wildiers J, Vermerin P, Lobelle JP, di Salle E, et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer, a phase I study. Anticancer Drugs 1998; 9:675-683.
15. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of Breast cancer. J Clin Oncol 2001; 19:881-894.
16. Tarkowski R, Skrzypczak M, Winiarczyk S, Kotarski J, Jakowicki JA, Jakimiuk AJ. Aromatase (P450 AROM) mRNA expression in normal, hyperplasic and malignant endometrium and aromatase activity in endometrial cancer tissue culture. Ginekol Pol 2000; 71:130-135.
17. Okubo T, Mok SC, Chen S. Regulation of aromatase expression in human ovarian surface epithelial cells. J Clin Endocrinol Metab 2000; 85:4889-4899.
18. Zimniski SJ, Garola RE, Fendl K, Peterson CM. Endocrine characterization of a human ovarian carcinoma (BG-1) established in nude mice. Steroids 2000; 54:593-606.
19. Zhou D, Wang J, Chen E, Murai J, Siiteri PK, Chen S. Aromatase gene is amplified in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 1993; 46:147-153.
20. Levin ER. Cellular function of the plasma membrane estrogen receptor. Trends Endocrinol Metab 1999; 10:374-377.
21. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15:2174-2183.
22. Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000; 82:501-513.